

Kejal Kantarci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6224308/publications.pdf>

Version: 2024-02-01

258
papers

20,448
citations

15466

65
h-index

13338

130
g-index

260
all docs

260
docs citations

260
times ranked

19080
citing authors

#	ARTICLE	IF	CITATIONS
1	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1907-1909.	1.9	0
2	The temporal onset of the core features in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2022, 18, 591-601.	0.4	19
3	Plug-and-play advanced magnetic resonance spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 2613-2620.	1.9	5
4	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2022, 112, 16-26.	1.5	9
5	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. <i>Brain Communications</i> , 2022, 4, fcac013.	1.5	15
6	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. <i>Acta Neuropathologica Communications</i> , 2022, 10, 16.	2.4	14
7	A novel computer adaptive word list memory test optimized for remote assessment: Psychometric properties and associations with neurodegenerative biomarkers in older women without dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12299.	1.2	8
8	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, 1495.	5.8	11
9	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2022, 37, 1256-1264.	2.2	11
10	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	4.5	29
11	Deep learning-based brain age prediction in normal aging and dementia. <i>Nature Aging</i> , 2022, 2, 412-424.	5.3	52
12	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1537-1547.	1.2	4
13	Face recognition from research brain PET: An unexpected PET problem. <i>NeuroImage</i> , 2022, 258, 119357.	2.1	6
14	Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy. <i>Annals of Neurology</i> , 2022, 92, 358-363.	2.8	5
15	Mitochondrial genomic variation in dementia with Lewy bodies: association with disease risk and neuropathological measures. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	0
16	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. <i>NeuroImage</i> , 2021, 224, 117433.	2.1	63
17	Association of Initial A β -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 217.	4.5	27
18	Brain volumetric deficits in MAPT mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	1.7	21

#	ARTICLE	IF	CITATIONS
19	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 99, 11-18.	1.5	11
20	Magnetic resonance spectroscopy in the rodent brain: Experts' consensus recommendations. <i>NMR in Biomedicine</i> , 2021, 34, e4325.	1.6	9
21	Across-vendor standardization of semi-LASER for single-voxel MRS at 3T. <i>NMR in Biomedicine</i> , 2021, 34, e4218.	1.6	43
22	Decreased glutamine and glutamate: an early biomarker of neurodegeneration. <i>International Psychogeriatrics</i> , 2021, 33, 1-2.	0.6	9
23	β -Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> , 2021, 96, .	1.5	13
24	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. <i>NeuroImage: Clinical</i> , 2021, 31, 102754.	1.4	27
25	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. <i>Frontiers in Neurology</i> , 2021, 12, 615024.	1.1	5
26	Peripheral Markers of Neurovascular Unit Integrity and Amyloid- β in the Brains of Menopausal Women. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 397-405.	1.2	4
27	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 396.	4.5	146
28	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.5	52
29	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 113-122.	1.2	8
30	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. <i>Journal of Neuroimaging</i> , 2021, 31, 1020-1027.	1.0	13
31	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. <i>NeuroImage</i> , 2021, 231, 117845.	2.1	38
32	Long-term ovarian hormone deprivation alters functional connectivity, brain neurochemical profile and white matter integrity in the Tg2576 amyloid mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 102, 139-150.	1.5	7
33	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. <i>Brain</i> , 2021, 144, 3212-3225.	3.7	26
34	Cerebral Microbleeds. <i>Stroke</i> , 2021, 52, 2347-2355.	1.0	9
35	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid- β PET Signal. <i>Neurology</i> , 2021, 97, e1799-e1808.	1.5	10
36	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. <i>NeuroImage</i> , 2021, 238, 118259.	2.1	24

#	ARTICLE	IF	CITATIONS
37	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
38	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
39	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	2.4	23
40	Sleep quality and cortical amyloid- β^2 deposition in postmenopausal women of the Kronos early estrogen prevention study. NeuroReport, 2021, 32, 326-331.	0.6	5
41	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.5	16
42	Tau Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	2.8	19
43	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. Nature Communications, 2021, 12, 7065.	5.8	38
44	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32
45	Risk factors of neurovascular ageing in women. Journal of Neuroendocrinology, 2020, 32, e12777.	1.2	12
46	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
47	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.4	32
48	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
49	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
50	Tau Positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
51	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology, 2020, 94, e15-e29.	1.5	25
52	β^2 -Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
53	β^2 -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
54	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74

#	ARTICLE	IF	CITATIONS
55	Associations of pituitary-ovarian hormones and white matter hyperintensities in recently menopausal women using hormone therapy. <i>Menopause</i> , 2020, 27, 872-878.	0.8	8
56	Association of common genetic variants with brain microbleeds. <i>Neurology</i> , 2020, 95, e3331-e3343.	1.5	40
57	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. <i>JAMA Network Open</i> , 2020, 3, e2022847.	2.8	19
58	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 2612.	5.8	283
59	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1195-1205.	1.4	30
60	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. <i>Brain</i> , 2020, 143, 2281-2294.	3.7	51
61	Subtypes of dementia with Lewy bodies are associated with α -synuclein and tau distribution. <i>Neurology</i> , 2020, 95, e155-e165.	1.5	47
62	Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. <i>Brain Communications</i> , 2020, 2, fcaa025.	1.5	37
63	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. <i>Frontiers in Neurology</i> , 2020, 11, 80.	1.1	13
64	Confirmation of ¹²³ I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1628-1635.	2.8	18
65	¹⁸ F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. <i>Brain Communications</i> , 2020, 2, fcaa040.	1.5	17
66	Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study. <i>Menopause</i> , 2020, 27, 305-310.	0.8	9
67	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. <i>Neurobiology of Aging</i> , 2020, 88, 42-50.	1.5	14
68	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 87, 556-567.	2.8	17
69	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1511-1523.	1.2	14
70	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. <i>Journal of Neurology</i> , 2020, 267, 1444-1453.	1.8	4
71	Reply to "Amyloid Positron Emission Tomography in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damage". <i>Annals of Neurology</i> , 2020, 87, 988-989.	2.8	0
72	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	1.7	17

#	ARTICLE	IF	CITATIONS
73	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, 743-755.	1.5	365
74	Reproductive history and progressive multiple sclerosis risk in women. <i>Brain Communications</i> , 2020, 2, fcaa185.	1.5	28
75	Revised Self-Monitoring Scale. <i>Neurology</i> , 2020, 94, e2384-e2395.	1.5	23
76	Rates of lobar atrophy in asymptomatic <i>MAPT</i> mutation carriers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 338-346.	1.8	22
77	<i>APOE</i> and cortical superficial siderosis in CAA. <i>Neurology</i> , 2019, 93, e358-e371.	1.5	42
78	Identification of Anonymous MRI Research Participants with Face-Recognition Software. <i>New England Journal of Medicine</i> , 2019, 381, 1684-1686.	13.9	124
79	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2019, 317, R912-R920.	0.9	15
80	The bivariate distribution of amyloid- β and tau: relationship with established neurocognitive clinical syndromes. <i>Brain</i> , 2019, 142, 3230-3242.	3.7	129
81	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. <i>Brain</i> , 2019, 142, 3621-3635.	3.7	37
82	Association of white matter microstructural integrity with cognition and dementia. <i>Neurobiology of Aging</i> , 2019, 83, 63-72.	1.5	32
83	Tracking white matter degeneration in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. <i>Neurobiology of Aging</i> , 2019, 83, 54-62.	1.5	14
84	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenocconversion in <i>Mapt</i> Mutation Carriers. <i>Journal of Neuroimaging</i> , 2019, 29, 624-629.	1.0	9
85	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.4	48
86	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. <i>Neurology</i> , 2019, 93, e29-e39.	1.5	62
87	White matter hyperintensities: relationship to amyloid and tau burden. <i>Brain</i> , 2019, 142, 2483-2491.	3.7	126
88	Reply to letter: Basis of cingulate island sign may differ in dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 761-762.	2.2	2
89	Investigation of white matter PiB uptake as a marker of white matter integrity. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 678-688.	1.7	18
90	Methodological consensus on clinical proton MRS of the brain: Review and recommendations. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 527-550.	1.9	280

#	ARTICLE	IF	CITATIONS
91	Entorhinal cortex tau, amyloid- β^2 , cortical thickness and memory performance in non-demented subjects. <i>Brain</i> , 2019, 142, 1148-1160.	3.7	68
92	Cerebrospinal fluid dynamics disorders. <i>Neurology</i> , 2019, 93, e2237-e2246.	1.5	19
93	The Kronos Early Estrogen Prevention Study (KEEPS). <i>Menopause</i> , 2019, 26, 1071-1084.	0.8	97
94	Association of Longitudinal β^2 -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. <i>JAMA Network Open</i> , 2019, 2, e1916439.	2.8	22
95	Cerebral microbleeds. <i>Neurology</i> , 2019, 92, e253-e262.	1.5	53
96	Development of ¹ H MRS biomarkers for tracking early predementia Alzheimer disease. <i>Neurology</i> , 2019, 92, 209-210.	1.5	7
97	¹⁸ F- β AV-1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. <i>Movement Disorders</i> , 2019, 34, 344-352.	2.2	26
98	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. <i>JAMA Neurology</i> , 2019, 76, 95.	4.5	69
99	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. <i>Neurology</i> , 2019, 93, e758-e765.	1.5	18
100	Joint associations of β^2 -amyloidosis and cortical thickness with cognition. <i>Neurobiology of Aging</i> , 2018, 65, 121-131.	1.5	27
101	White Matter Reference Region in PET Studies of ¹¹ C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid- β^2 Deposition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1583-1589.	2.8	37
102	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. <i>Neurology</i> , 2018, 90, e1404-e1412.	1.5	57
103	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. <i>Journal of Human Hypertension</i> , 2018, 32, 385-385.	1.0	0
104	Frequency of Acute and Subacute Infarcts in a Population-Based Study. <i>Mayo Clinic Proceedings</i> , 2018, 93, 300-306.	1.4	5
105	AutoVOI: real-time automatic prescription of volume of interest for single voxel spectroscopy. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1787-1798.	1.9	32
106	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 210-216.	1.2	19
107	Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis. <i>Menopause</i> , 2018, 25, 625-634.	0.8	17
108	Cervical spinal cord atrophy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e435.	3.1	57

#	ARTICLE	IF	CITATIONS
109	In vivo ¹⁸ F-AV-1451 tau PET signal in <i>MAPT</i> mutation carriers varies by expected tau isoforms. <i>Neurology</i> , 2018, 90, e947-e954.	1.5	60
110	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. <i>Neurology</i> , 2018, 90, e466-e473.	1.5	55
111	Clinicopathological and ¹²³ I-â€œFP-â€œCIT SPECT correlations in patients with dementia. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 376-381.	1.7	11
112	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. <i>Brain</i> , 2018, 141, 271-287.	3.7	218
113	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	3.7	309
114	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 739-749.	1.4	34
115	Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1241-1250.	1.9	38
116	Association Between Microinfarcts and Blood Pressure Trajectories. <i>JAMA Neurology</i> , 2018, 75, 212.	4.5	15
117	The limbic and neocortical contribution of α -synuclein, tau, and amyloid β^2 to disease duration in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2018, 14, 330-339.	0.4	69
118	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. <i>Annals of Neurology</i> , 2018, 84, 705-716.	2.8	49
119	Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study. <i>Maturitas</i> , 2018, 117, 64-77.	1.0	10
120	Loss of Ovarian Hormones and Accelerated Somatic and Mental Aging. <i>Physiology</i> , 2018, 33, 374-383.	1.6	35
121	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. <i>NeuroImage: Clinical</i> , 2018, 19, 939-947.	1.4	31
122	Multimodal imaging in RBD " present and future. <i>Nature Reviews Neurology</i> , 2018, 14, 574-576.	4.9	1
123	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. <i>Alzheimer's and Dementia</i> , 2018, 14, 1171-1183.	0.4	468
124	Duration and Pathologic Correlates of Lewy Body Disease. <i>JAMA Neurology</i> , 2017, 74, 310.	4.5	48
125	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). <i>Acta Neuropathologica</i> , 2017, 133, 705-715.	3.9	125
126	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. <i>JAMA Neurology</i> , 2017, 74, 801.	4.5	81

#	ARTICLE	IF	CITATIONS
127	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
128	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 172-179.	1.5	158
129	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. <i>Journal of Neurology</i> , 2017, 264, 938-945.	1.8	24
130	Preeclampsia and cognitive impairment later in life. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 74.e1-74.e11.	0.7	93
131	Prevalence and Natural History of Superficial Siderosis. <i>Stroke</i> , 2017, 48, 3210-3214.	1.0	40
132	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. <i>Cortex</i> , 2017, 97, 143-159.	1.1	162
133	Uptake of AV-1451 in meningiomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 736-743.	1.2	7
134	Neuroimaging Correlates of Cerebral Microbleeds. <i>Stroke</i> , 2017, 48, 2964-2972.	1.0	63
135	Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. <i>Journal of Hypertension</i> , 2017, 35, 2479-2485.	0.3	19
136	Midlife and Late-Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	54
137	Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 339-347.	1.8	43
138	Myelopathy in Behçet's disease: The Bagel Sign. <i>Annals of Neurology</i> , 2017, 82, 288-298.	2.8	46
139	Decreased Glutamate Levels in Patients with Amnesic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiB-PET Study. <i>Journal of Neuroimaging</i> , 2017, 27, 630-636.	1.0	29
140	AV-1451 tau and β -amyloid positron emission tomography imaging in dementia with Lewy bodies. <i>Annals of Neurology</i> , 2017, 81, 58-67.	2.8	152
141	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 257-266.	0.4	41
142	Regional T_1 relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 774-778.	1.9	17
143	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.4	581
144	[O2-07-06]: CHANGES IN BRAIN STRUCTURE THREE YEARS AFTER THE END OF MENOPAUSAL HORMONE THERAPIES IN A RANDOMIZED CONTROLLED TRIAL. <i>Alzheimer's and Dementia</i> , 2017, 13, P570.	0.4	2

#	ARTICLE	IF	CITATIONS
145	Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA). <i>BMJ Open</i> , 2017, 7, e018861.	0.8	30
146	[O1â€™02â€™04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P186.	0.4	0
147	¹ H-MRS metabolites and rate of β^2 -amyloid accumulation on serial PET in clinically normal adults. <i>Neurology</i> , 2017, 89, 1391-1399.	1.5	18
148	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1069-1082.	1.2	30
149	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 5-14.	1.2	17
150	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2016, 45, 107-108.	1.5	21
151	MR spectroscopy, <i>APOE</i> genotype, and evolving β^2 -amyloid pathology. <i>Neurology</i> , 2016, 86, 1750-1751.	1.5	2
152	Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S70-6.	0.9	63
153	Magnetic Resonance Spectroscopy in Dementia. , 2016, , 55-70.		0
154	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016, 31, 1619-1622.	2.2	55
155	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. <i>Neurology: Genetics</i> , 2016, 2, e85.	0.9	16
156	An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2016, 26, 264-268.	1.0	3
157	Effects of hormone therapy on brain structure. <i>Neurology</i> , 2016, 87, 887-896.	1.5	47
158	An autoradiographic evaluation of AV-1451 Tau PET in dementia. <i>Acta Neuropathologica Communications</i> , 2016, 4, 58.	2.4	388
159	LRRK2 variation and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 98-103.	1.1	30
160	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. <i>NeuroImage: Clinical</i> , 2016, 11, 802-812.	1.4	249
161	Amyloid- β^2 deposition and regional grey matter atrophy rates in dementia with Lewy bodies. <i>Brain</i> , 2016, 139, 2740-2750.	3.7	68
162	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. <i>Neurology</i> , 2016, 87, 691-698.	1.5	22

#	ARTICLE	IF	CITATIONS
163	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	1.5	20
164	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. <i>Neurology</i> , 2016, 87, 2317-2323.	1.5	44
165	Early Postmenopausal Transdermal 17 β -Estradiol Therapy and Amyloid- β Deposition. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 547-556.	1.2	94
166	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2016, 12, 1297-1304.	0.4	32
167	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. <i>Movement Disorders</i> , 2016, 31, 989-994.	2.2	32
168	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2016, 139, 1005-1007.	3.7	6
169	Plasma sphingolipid changes with autopsy-confirmed Lewy body or Alzheimer's pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 43-50.	1.2	44
170	Atrial fibrillation, cognitive impairment, and neuroimaging. <i>Alzheimer's and Dementia</i> , 2016, 12, 391-398.	0.4	58
171	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 633-643.	1.2	27
172	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. <i>Sleep Medicine</i> , 2015, 16, 1502-1510.	0.8	45
173	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1109-1117.	1.2	19
174	Clinicopathologic and ¹¹ C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	3.7	270
175	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1101-1104.	1.1	27
176	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015, 11, 740-756.	0.4	142
177	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	3.7	222
178	Vascular Imaging Abnormalities and Cognition. <i>Stroke</i> , 2015, 46, 433-440.	1.0	125
179	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. <i>Neurobiology of Aging</i> , 2015, 36, 2010-2017.	1.5	35
180	Role of β -Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2015, 72, 1475.	4.5	23

#	ARTICLE	IF	CITATIONS
181	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 452-461.	1.5	113
182	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2015, 25, 269-274.	1.0	24
183	Fractional Anisotropy of the Fornix and Hippocampal Atrophy in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 316.	1.7	63
184	Antemortem MRI findings associated with microinfarcts at autopsy. <i>Neurology</i> , 2014, 82, 1951-1958.	1.5	45
185	Association of hypometabolism and amyloid levels in aging, normal subjects. <i>Neurology</i> , 2014, 82, 1959-1967.	1.5	73
186	Past hormone therapy in older women. <i>Neurology</i> , 2014, 82, 380-381.	1.5	0
187	Long-Term Exercise Training for an Individual With Mixed Corticobasal Degeneration and Progressive Supranuclear Palsy Features: 10-Year Case Report Follow-up. <i>Physical Therapy</i> , 2014, 94, 289-296.	1.1	26
188	The Role of Diffusion Tensor Imaging in Detecting Microstructural Changes in Prodromal Alzheimer's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 3-9.	1.9	55
189	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. <i>Neurology</i> , 2014, 83, 1771-1772.	1.5	6
190	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	1.7	117
191	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. <i>JAMA Neurology</i> , 2014, 71, 1547.	4.5	57
192	Dementia with Lewy bodies. <i>Neurology</i> , 2014, 83, 801-809.	1.5	143
193	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2014, 35, 1483-1490.	1.5	29
194	Microbleeds in the logopenic variant of primary progressive aphasia. <i>Alzheimer's and Dementia</i> , 2014, 10, 62-66.	0.4	14
195	Association of type 2 diabetes with brain atrophy and cognitive impairment. <i>Neurology</i> , 2014, 82, 1132-1141.	1.5	180
196	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. <i>Alzheimer's and Dementia</i> , 2014, 10, 779-789.	0.4	26
197	Lesional REM sleep behavior disorder localizes to the dorsomedial pons. <i>Neurology</i> , 2014, 83, 1871-1873.	1.5	40
198	Diabetes and Elevated Hemoglobin A1c Levels Are Associated with Brain Hypometabolism but Not Amyloid Accumulation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 759-764.	2.8	134

#	ARTICLE	IF	CITATIONS
199	Clinical Proton MR Spectroscopy in Central Nervous System Disorders. <i>Radiology</i> , 2014, 270, 658-679.	3.6	524
200	¹⁸ F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. <i>Neurobiology of Aging</i> , 2014, 35, 2096-2106.	1.5	108
201	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. <i>NeuroImage</i> , 2014, 94, 65-78.	2.1	155
202	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 493-498.	1.1	49
203	MRS in Early and Presymptomatic Carriers of a Novel Octapeptide Repeat Insertion in the Prion Protein Gene. <i>Journal of Neuroimaging</i> , 2013, 23, 409-413.	1.0	1
204	Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause. <i>Biology of Sex Differences</i> , 2013, 4, 6.	1.8	52
205	Magnetic Resonance Spectroscopy in Common Dementias. <i>Neuroimaging Clinics of North America</i> , 2013, 23, 393-406.	0.5	44
206	Nonamnesic mild cognitive impairment progresses to dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 2032-2038.	1.5	191
207	MRI and MRS predictors of mild cognitive impairment in a population-based sample. <i>Neurology</i> , 2013, 81, 126-133.	1.5	95
208	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. <i>Neurology</i> , 2013, 81, 1681-1689.	1.5	58
209	Focal hemosiderin deposits and β -amyloid load in the ADNI cohort. <i>Alzheimer's and Dementia</i> , 2013, 9, S116-23.	0.4	59
210	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. <i>Neurology</i> , 2013, 80, 911-918.	1.5	86
211	Dementia and Alzheimer Disease: Evidence-Based Neuroimaging. , 2013, , 283-298.		0
212	Brain injury biomarkers are not dependent on β -amyloid in normal elderly. <i>Annals of Neurology</i> , 2013, 73, 472-480.	2.8	155
213	Elevated occipital β -amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1357-1364.	0.9	28
214	Proton MRS in mild cognitive impairment. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 770-777.	1.9	62
215	Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With β -Amyloidosis. <i>JAMA Neurology</i> , 2013, 70, 1030.	4.5	65
216	Magnetic resonance spectroscopy in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 687.	1.0	61

#	ARTICLE	IF	CITATIONS
217	Imaging markers offer promise. <i>Neurology</i> , 2012, 79, 2296-2297.	1.5	0
218	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. <i>Brain</i> , 2012, 135, 765-783.	3.7	322
219	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 856-67.	4.9	99
220	Early indications of magnetic resonance spectroscopy changes associated with β -amyloid load in the cognitively normal. <i>Future Neurology</i> , 2012, 7, 117-118.	0.9	0
221	Effect of lifestyle activities on alzheimer disease biomarkers and cognition. <i>Annals of Neurology</i> , 2012, 72, 730-738.	2.8	149
222	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: A case series. <i>Neurocase</i> , 2012, 18, 1-12.	0.2	9
223	Ante mortem amyloid imaging and β -amyloid pathology in a case with dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 878-885.	1.5	69
224	Multimodality imaging characteristics of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2012, 33, 2091-2105.	1.5	162
225	Non-Stationarity in the "Resting Brain"™s Modular Architecture. <i>PLoS ONE</i> , 2012, 7, e39731.	1.1	382
226	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. <i>Brain</i> , 2012, 135, 2470-2477.	3.7	64
227	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. <i>Neurology</i> , 2012, 79, 553-560.	1.5	91
228	An operational approach to National Institute on Aging's Alzheimer's Association criteria for preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2012, 71, 765-775.	2.8	520
229	Magnetic resonance spectroscopy, β -amyloid load, and cognition in a population-based sample of cognitively normal older adults. <i>Neurology</i> , 2011, 77, 951-958.	1.5	63
230	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. <i>NeuroImage</i> , 2011, 55, 522-531.	2.1	90
231	Time-to-event voxel-based techniques to assess regional atrophy associated with MCI risk of progression to AD. <i>NeuroImage</i> , 2011, 54, 985-991.	2.1	25
232	Diffusion Tensor Imaging in Alzheimers Disease. <i>Current Medical Imaging</i> , 2011, 7, 28-33.	0.4	4
233	Clinical Characterization of a Kindred With a Novel 12-Octapeptide Repeat Insertion in the Prion Protein Gene. <i>Archives of Neurology</i> , 2011, 68, 1165.	4.9	25
234	Untreated Type 2 Diabetes and Its Complications Are Associated With Subcortical Infarctions. <i>Diabetes Care</i> , 2011, 34, 184-186.	4.3	66

#	ARTICLE	IF	CITATIONS
235	Clinical Correlates of White Matter Tract Degeneration in Progressive Supranuclear Palsy. Archives of Neurology, 2011, 68, 753-60.	4.9	110
236	10 Neuroimaging in Alzheimer Disease. , 2011, , 167-182.		0
237	Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment. American Journal of Neuroradiology, 2010, 31, 1247-1253.	1.2	48
238	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	3.7	195
239	Alzheimer's disease diagnosis in individual subjects using structural MR images: Validation studies. NeuroImage, 2008, 39, 1186-1197.	2.1	391
240	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
241	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 1621-8.	4.9	75
242	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem ¹ MR Spectroscopy Metabolite Measurements ¹ . Radiology, 2008, 248, 210-220.	3.6	147
243	Patterns of Atrophy Differ Among Specific Subtypes of Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1130.	4.9	185
244	Imaging correlates of posterior cortical atrophy. Neurobiology of Aging, 2007, 28, 1051-1061.	1.5	176
245	Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1330-1339.	1.5	185
246	The Role of Biomarkers in Clinical Trials for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 6-15.	0.6	203
247	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain, 2006, 129, 3103-3114.	3.7	105
248	Neuroimaging in Alzheimer Disease. , 2006, , 142-159.		3
249	Magnetic resonance markers for early diagnosis and progression of Alzheimer's disease. Expert Review of Neurotherapeutics, 2005, 5, 663-670.	1.4	30
250	Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151.		23
251	Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx, 2004, 1, 196-205.	6.0	80
252	Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease. Clinical Neurophysiology, 2003, 114, 1724-1728.	0.7	59

#	ARTICLE	IF	CITATIONS
253	Neuroimaging in Alzheimer disease: an evidence-based review. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 197-209.	0.5	193
254	Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. <i>American Journal of Neuroradiology</i> , 2003, 24, 843-9.	1.2	92
255	¹ H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2002, 8, 934-942.	1.2	109
256	Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 14, 198-207.	0.7	135
257	Mild Cognitive Impairment and Alzheimer Disease: Regional Diffusivity of Water. <i>Radiology</i> , 2001, 219, 101-107.	3.6	293
258	Proton MR spectroscopy in aging and dementia. , 0, , 618-629.		0